Hepatocellular Cancer Withdrawn Phase 1 Trials for Sorafenib (DB00398)

Also known as: Cancer, Hepatocellular

IndicationStatusPhase
DBCOND0037277 (Hepatocellular Cancer)Withdrawn1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01618253Radiation Therapy With Sorafenib for TACE-Resistant Hepatocellular CarcinomaTreatment
NCT02288507Sorafenib Concurrent With Yttrium-90 Transarterial Radioembolization in Patients With Advanced Hepatocellular CancerTreatment